Key Points
- CFO Kevin Brady sold 3,000 shares of Medpace on Nov. 21 at an average price of $590.35 for about $1.77M, cutting his holding by 33.3% to 6,000 shares (disclosed in an SEC filing).
- Medpace posted a strong quarter, reporting $3.86 EPS (vs. $3.50 consensus) and $659.9M revenue (up 23.7% YoY), and set FY2025 guidance of $14.600–14.860 EPS.
- Market valuation and sentiment: shares trade near $612 with a $17.23B market cap and a PE of ~42.8, while analysts’ consensus is a "Hold" with a $487.18 target amid mixed ratings.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CFO Kevin Brady sold 3,000 shares of the firm's stock in a transaction on Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the transaction, the chief financial officer directly owned 6,000 shares of the company's stock, valued at $3,542,100. This represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Medpace Price Performance
NASDAQ:MEDP opened at $611.81 on Wednesday. The firm's 50-day moving average price is $554.32 and its 200-day moving average price is $439.13. The company has a market capitalization of $17.23 billion, a PE ratio of 42.78, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter in the previous year, the firm posted $3.01 earnings per share. Medpace's quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Institutional Investors Weigh In On Medpace
Institutional investors have recently modified their holdings of the business. Nordea Investment Management AB lifted its stake in Medpace by 4.8% during the 2nd quarter. Nordea Investment Management AB now owns 61,125 shares of the company's stock valued at $19,067,000 after acquiring an additional 2,792 shares during the period. Arkadios Wealth Advisors purchased a new position in shares of Medpace during the second quarter valued at approximately $327,000. Inspire Investing LLC purchased a new position in shares of Medpace during the first quarter valued at approximately $2,059,000. Truist Financial Corp lifted its position in Medpace by 10.2% during the second quarter. Truist Financial Corp now owns 12,898 shares of the company's stock valued at $4,048,000 after purchasing an additional 1,197 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Medpace by 10.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company's stock worth $371,000 after purchasing an additional 111 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms recently weighed in on MEDP. Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and raised their price objective for the company from $342.00 to $474.00 in a research report on Wednesday, September 3rd. TD Cowen raised their price target on Medpace from $356.00 to $462.00 and gave the company a "sell" rating in a report on Friday, October 24th. Truist Financial set a $555.00 price target on shares of Medpace in a research note on Monday, October 27th. Robert W. Baird set a $613.00 price objective on shares of Medpace in a research note on Friday, October 24th. Finally, Zacks Research raised shares of Medpace from a "hold" rating to a "strong-buy" rating in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $487.18.
Get Our Latest Research Report on MEDP
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
